All anti-CD20 monoclonal antibodies have similar efficacy and risks: Commentary.

Abstract

The progress in understanding the pathophysiology of multiple sclerosis (MS) by recognizing the role of B-cells has led to a paradigm shift in managing MS. The role of B-cells is supported by the detection of intrathecal immunoglobulins, brain-specific antibodies, B-cells in the meninges, and the cerebrospinal fluid in MS patients.1 In addition to the results of prospective trials targeting CD20, a non-glycosylated transmembrane protein is predominantly found on the surface of B-cells2 and recently identified in about 3%–5% of T-cells.3